10 Nov 2008

Drug development expert joining aCROnordic

As of 1 November Karen Koch (M.Sc. Pharmacy and Pharmaceutical Medicine) joined aCROnordic as Principle Development Consultant. With significant experience Karen Koch further strengthens the development profile of the company.

- Karen has been involved in literally all phases of drug development. Existing and new customers in drug development will benefit tremendously from her outstanding expertise, says Birgitte Guldhammer, Executive Vice President at aCROnordic.

Karen Koch has three decades of product development experience from the pharmaceutical industry, enclosing clinical development, clinical regulatory, CMC and pre-clinical safety, project management, intellectual property rights, and licensing.

aCROnordic works continuously for embracing know-how on the entire drug development process. We challenge ongoing processes and drive development programmes efficiently.

- In drug development we want to be a long term partner, instead of just an individual service vendor. The employment of Karen adds further to this commitment, and I am exited to work with her on this project, says Birgitte Guldhammer.

Karen Koch has previously been with NovoNordisk and Genmab, and she joins aCROnordic from Natimmune A/S

aCROnordic A/S • Scion DTU • Kogle Allé 5 • DK-2970 Hørsholm • Denmark • Phone: +45 4516 8800 • info@aCROnordic.com